Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension

Nephrology Dialysis Transplantation

Volumn 15, Issue 1, 2000, Pages 82-86

  Calviño, Jesús ^a   Lens, Xose M ^a   Romero, Rafael ^a   Sánchez Guisande, Domingo ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Anaemia; Hypertension; Losartan; Proteinuria; Renal transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CYCLOSPORIN A; HEMOGLOBIN; LOSARTAN; PROTEIN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; FEMALE; HEMOGLOBINOPATHY; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEINURIA;

EID: 0033981803     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.1.82     Document Type: Article

References (21)

1. Peeters J, Roels L, Vanrenterghem Y. Chronic renal allograft failure: Clinical overview. Kidney Int 1995; 48 [Suppl 52]: S97-S101
2. Raine AEG. Does antihypertensive therapy modify chronic allograft failure? Kidney Int 1995; 48 [Suppl 52]: S107-S111
3. Rosenberg ME, Lawrence JS, Correa-Rotter R, Hosteller TH. The paradox of the renin angiotensin system in chronic renal disease. Kidney Int 1994; 45: 403-410
4. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP. Inhibition of angiotensin converting enzyme in renal transplant recipients with hypertension. N Engl J Med 1983; 308: 377-381
5. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-673
6. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991; 17: 199-205
7. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654
8. Ducloux D, Saint-Hillier Y, Chalopin JM. Effect of Losartan on haemoglobin concentration in renal transplant recipients a retrospective analysis. Nephrol Dial Transplant 1997; 12: 2683-2686
9. Klaassen RJL, Van Gelder T, Rischen-Vos J, Deinum J, Man in't Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with postransplant erythrocytosis. Transplantation 1997; 64: 780-782
10. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471-475
11. Traindl O, Falger S, Reading S et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55: 1309-1313
12. Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, Bordes J, Herrera-Acosta J. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38: 873-879
13. Pitt B, Segal R, Martinez FA et al., on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-752
14. Nabokov A, Amann K, Gassmann P, Schwarz U, Orth SR, Ritz E. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998; 13: 173-176
15. Gansevoort RT, de Zeevw D, Jong PE. Is the proteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 1994; 45; 861-867
16. Nielsen S, Dollerup J, Nielsen B, Jensen HÆ, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 19-23
17. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyó JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998; 68 [Suppl]: 130-134
18. Schwarzbeck A, Wittenmeier KW, Hällfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352: 286
19. Morrone LF, di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena P. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients. Transplantation 1997; 64: 913-918
20. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314
21. Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment. Blood Press 1996; 5: 190-191